Valvular & structural heart disease
Pulmonary Artery Pulsatility Index and Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Replacement
Corrected 23 Oct 2026: Measure wording clarified; no values changed.
Authors' conclusion
In patients undergoing TTVR, low preprocedural PAPI identifies a high-risk phenotype, and it is independently associated with adverse outcomes.
Study context
- Population
- Patients with severe tricuspid regurgitation undergoing orthotopic transcatheter tricuspid valve replacement (TTVR) with preprocedural right heart catheterization data
- Participants
- 94 patients
- Exposure
- Low pulmonary artery pulsatility index (PAPI) vs high PAPI
- Low PAPIn = 28
- Outcome
- Composite of:
- All-cause mortality
- HF hospitalization
- Follow-up
- 2-year follow-up
Methodological detailsMedian follow-up 491 days (Q1-Q3: 227-879 days)
- Median follow-up 491 days (Q1-Q3: 227-879 days)
Main finding
As reported in the abstract
Survival free from composite endpoint (Kaplan-Meier)
HR for the composite of all-cause mortality and heart failure hospitalization
2.50
95% CI 1.18–5.27
P = 0.018
By group
Low PAPIvs High PAPI
HR for the composite of all-cause mortality and heart failure hospitalization 2.50 (95% CI 1.18–5.27); P = 0.018
Observational data: associations, not effects.
Further findings
| Outcome | Low PAPI | High PAPI | P value |
|---|---|---|---|
| Survival free from all-cause mortality (Kaplan-Meier) | 52.6% (95% CI 30.2%–91.7%) | 87.6% (95% CI 79.2%–96.9%) | P = 0.006 |
| Survival free from HF hospitalization (Kaplan-Meier) | 49.1% (95% CI 28.4%–85.1%) | 76.6% (95% CI 65.4%–89.6%) | P = 0.017 |
Original publication
Pulmonary Artery Pulsatility Index and Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Replacement. JACC Cardiovasc Interv. Published 11 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →